Ibrance vs Trelegy Ellipta
Side-by-side drug price comparison from Medicare Part D data
Verdict
Trelegy Ellipta costs 96% less per claim than Ibrance ($380.00 vs $10816.00). Ibrance has a generic alternative available. Total Medicare spending: Ibrance at $4.5B vs Trelegy Ellipta at $2.9B.
| Metric | Ibrance | Trelegy Ellipta |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $10,816 | $380* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $4.5B | $2.9B |
| Total Claims | 418,000 | 7,560,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | -5.6%* | 19.8% |
| Generic Available | Yes | No |
| Condition | Cancer | Asthma/COPD |
| Total Beneficiaries | 36,000 | 865,000 |
Trelegy Ellipta costs 96% less per claim than Ibrance ($380.00 vs $10816.00). Ibrance has a generic alternative available. Total Medicare spending: Ibrance at $4.5B vs Trelegy Ellipta at $2.9B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both entity A and entity B. What follows is the interpretation — which specific axes carry the most weight for entity A versus entity B, and which differences are large enough to influence a real decision.
Practical use of the comparison: read the data above, then drill into the individual entity A and entity B detail pages for the underlying breakdown. A pairwise comparison answers the relative question; the per-entity pages answer the absolute question.
Source: CMS Medicare Part D Spending, 2026.